Other new targeted approaches for R/R DLBCL have been recently approved, as the combination of tafasitamab (anti-CD19 monoclonal antibody) and lenalidomide (20), the combination of polatuzumab vedotin with bendamustine and rituximab (21), and selinexor, an oral inhibitor of exportin 1 (approved by the FDA but not by the EMA) (22). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.